Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, s.c. Clear all
Not yet recruiting Early Phase 1 Interventional

hCG Treatment for Rehabilitation From a TBI

NCT07557615
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Ovidrel, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

NCT01716754
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 4, 2026, 10:56 AM EDT
Active, not recruiting Phase 3 Interventional

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anniston, Alabama • Walnut Creek, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Recruiting Phase 3 Interventional

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630
View directory record Official record
Conditions
Obesity, Knee Osteoarthritis (OA)
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111 )
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Walnut Creek, California • Hamden, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

NCT02527200
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Santa Monica, California • Baltimore, Maryland • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02863419
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Los Alamitos, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0519-0130, Placebo, Trizepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
55
States / cities
Chula Vista, California • Fresno, California • Inglewood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Active, not recruiting Phase 2 Interventional

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

NCT05928390
View directory record Official record
Conditions
Post-Bariatric Hypoglycemia
Interventions
Pasireotide Diaspartate
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Palo Alto, California • Chicago, Illinois • Metairie, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Recruiting Phase 3 Interventional

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

NCT02098395
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

NCT02918279
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 17 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Meridian, Idaho • Baton Rouge, Louisiana • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

NCT06737536
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Placebo (NNC0662-0419)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
19 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

NCT01892436
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
22
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 4, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0662-0419, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Lancaster, California • Lomita, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

NCT02305381
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
72
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

NCT00620282
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 4, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

NCT01688882
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

NCT02461589
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
84
States / cities
Birmingham, Alabama • Coronado, California • Lancaster, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

NCT01350804
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo, Abatacept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
44
States / cities
Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 4, 2026, 10:56 AM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT06015893
View directory record Official record
Conditions
Addiction, Alcohol Use Disorder
Interventions
Take Control, Semaglutide
Behavioral · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 110 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
QGE031, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 4, 2026, 10:56 AM EDT
Recruiting Phase 3 Interventional

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT07533175
View directory record Official record
Conditions
Diabetes Mellitus, Overweight, Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Lomita, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 4, 2026, 10:56 AM EDT